212 related articles for article (PubMed ID: 28729967)
1. Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease.
Sweeney WE; Frost P; Avner ED
World J Nephrol; 2017 Jul; 6(4):188-200. PubMed ID: 28729967
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability.
Sweeney WE; Hamahira K; Sweeney J; Garcia-Gatrell M; Frost P; Avner ED
Kidney Int; 2003 Oct; 64(4):1310-9. PubMed ID: 12969149
[TBL] [Abstract][Full Text] [Related]
3. Renal dysfunction but not cystic change is ameliorated by neonatal epidermal growth factor in bpk mice.
Nakanishi K; Gattone VH; Sweeney WE; Avner ED
Pediatr Nephrol; 2001 Jan; 16(1):45-50. PubMed ID: 11198603
[TBL] [Abstract][Full Text] [Related]
4. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor.
Sweeney WE; Chen Y; Nakanishi K; Frost P; Avner ED
Kidney Int; 2000 Jan; 57(1):33-40. PubMed ID: 10620185
[TBL] [Abstract][Full Text] [Related]
5. Src inhibition ameliorates polycystic kidney disease.
Sweeney WE; von Vigier RO; Frost P; Avner ED
J Am Soc Nephrol; 2008 Jul; 19(7):1331-41. PubMed ID: 18385429
[TBL] [Abstract][Full Text] [Related]
6. A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease.
Dell KM; Nemo R; Sweeney WE; Levin JI; Frost P; Avner ED
Kidney Int; 2001 Oct; 60(4):1240-8. PubMed ID: 11576338
[TBL] [Abstract][Full Text] [Related]
7. Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease.
Jia G; Kwon M; Liang HL; Mortensen J; Nilakantan V; Sweeney WE; Park F
Pediatr Nephrol; 2010 Jun; 25(6):1139-46. PubMed ID: 20229187
[TBL] [Abstract][Full Text] [Related]
8. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.
Wang X; Harris PC; Somlo S; Batlle D; Torres VE
Nephrol Dial Transplant; 2009 Feb; 24(2):526-34. PubMed ID: 18826972
[TBL] [Abstract][Full Text] [Related]
9. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
Masyuk T; Masyuk A; Trussoni C; Howard B; Ding J; Huang B; LaRusso N
JHEP Rep; 2021 Oct; 3(5):100345. PubMed ID: 34568801
[TBL] [Abstract][Full Text] [Related]
10. Hypomagnesaemia is absent in children with autosomal dominant polycystic kidney disease.
Seeman T; Fořtová M; Sopko B; Průša R; Pohl M; John U
Ann Clin Biochem; 2019 Jan; 56(1):90-94. PubMed ID: 29874928
[TBL] [Abstract][Full Text] [Related]
11. Multi-parametric MRI of kidney disease progression for autosomal recessive polycystic kidney disease: mouse model and initial patient results.
MacAskill CJ; Erokwu BO; Markley M; Parsons A; Farr S; Zhang Y; Tran U; Chen Y; Anderson CE; Serai S; Hartung EA; Wessely O; Ma D; Dell KM; Flask CA
Pediatr Res; 2021 Jan; 89(1):157-162. PubMed ID: 32283547
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic analysis of conditionally immortalized cells isolated from the BPK model of ARPKD.
Sweeney WE; Kusner L; Carlin CR; Chang S; Futey L; Cotton CU; Dell KM; Avner ED
Am J Physiol Cell Physiol; 2001 Nov; 281(5):C1695-705. PubMed ID: 11600434
[TBL] [Abstract][Full Text] [Related]
13. Autosomal recessive and dominant polycystic kidney diseases.
Sessa A; Righetti M; Battini G
Minerva Urol Nefrol; 2004 Dec; 56(4):329-38. PubMed ID: 15785425
[TBL] [Abstract][Full Text] [Related]
14. Therapies to slow polycystic kidney disease.
Torres VE
Nephron Exp Nephrol; 2004; 98(1):e1-7. PubMed ID: 15361692
[TBL] [Abstract][Full Text] [Related]
15. Initial evaluation of hepatic T1 relaxation time as an imaging marker of liver disease associated with autosomal recessive polycystic kidney disease (ARPKD).
Gao Y; Erokwu BO; DeSantis DA; Croniger CM; Schur RM; Lu L; Mariappuram J; Dell KM; Flask CA
NMR Biomed; 2016 Jan; 29(1):84-9. PubMed ID: 26608869
[TBL] [Abstract][Full Text] [Related]
16. Modulation of P2X
Xu B; Nikolaienko O; Levchenko V; Choubey AS; Isaeva E; Staruschenko A; Palygin O
Physiol Rep; 2022 Nov; 10(21):e15510. PubMed ID: 36353932
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
18. Emerging Therapies for Childhood Polycystic Kidney Disease.
Sweeney WE; Avner ED
Front Pediatr; 2017; 5():77. PubMed ID: 28473970
[TBL] [Abstract][Full Text] [Related]
19. Sonographic pattern of recessive polycystic kidney disease in young adults. Differences from the dominant form.
Nicolau C; Torra R; Badenas C; Pérez L; Oliver JA; Darnell A; Brú C
Nephrol Dial Transplant; 2000 Sep; 15(9):1373-8. PubMed ID: 10978393
[TBL] [Abstract][Full Text] [Related]
20. Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model.
Wang X; Constans MM; Chebib FT; Torres VE; Pellegrini L
Am J Nephrol; 2019; 49(6):487-493. PubMed ID: 31117065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
